Global bio-pharmaceutical company, Sanofi finds itself in varied situations. There is apparent disappointment following the joint efforts with Janssen to develop an E. coli vaccine which proved inefficient in phase 3 trials, resulting in a $250M loss. On leadership changes, new bosses arrive at the company in the new year. The company is amid legalities as it tangles with Sanofi over commercial transparency, and with HHS defending its 340B rebate policy.
Despite the hurdles, Sanofi continues to innovate with groundbreaking partnerships such as with Regeneron in the Dupixent collaboration and with AQEMIA in R&D. Sanofi announces a significant share buyback of up to 2 billion euros, and the stocks are being acquired by principals such as Van ECK Associates Corp. Enhanced growth is planned through a planned €1B insulin 'manufacturing base' in Beijing which is Sanofi’s biggest investment in China to date. Further financial triumph is anticipated with a $16 bln stake sale in its consumer unit to CD&R.
Sanofi News Analytics from Mon, 29 Apr 2024 07:00:00 GMT to Sat, 15 Feb 2025 09:44:36 GMT - Rating -3 - Innovation 5 - Information 6 - Rumor -2
